XBiotech, Inc. Stock News
$6.66
4.45%
yesterday
Nasdaq,
Nov 15, 10:00 pm CET
XBiotech, Inc. Stock News
Neutral
GlobeNewsWire
●
5 months ago
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy
Neutral
Seeking Alpha
●
6 months ago
XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke. Other studies being deployed are Natrunix for the treatment of patients with pancreatic cancer and rheumatoid arthritis. While other biologics have targeted IL-1, none have been established to specifically target IL-1a.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
